Tepadina 400 mg (Thiotepa POWDER FOR SOLUTION) 400 MG

TePadina 400 mg is a powder for solution containing Thiotepa, used for various medical purposes. This intravenous medication is manufactured by Adienne SA in Switzerland.

Strength

400 MG

Manufacturer / TM Owner

ADIENNE SA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TePadina 400 mg, containing the active ingredient Thiotepa, is generally used in medical settings for its cytotoxic properties. It is often administered intravenously for conditions requiring chemotherapy. The primary use of Thiotepa is to target rapidly dividing cells, making it suitable for certain types of cancer treatments. Patients and healthcare providers commonly seek information on what Thiotepa is used for, particularly in oncology.

Side Effects

When administered intravenously, TePadina 400 mg may cause various effects due to its cytotoxic nature. Common effects can include nausea, vomiting, and fatigue. Some patients may experience bone marrow suppression, leading to a decrease in blood cell counts. These effects are typically managed under medical supervision to ensure patient safety and comfort.

Precautions & Warnings

TePadina 400 mg should be handled with care due to its potent nature. It is essential to follow proper safety protocols when preparing and administering this medication. Patients should be monitored closely for any adverse reactions. Pregnant women and individuals with certain medical conditions should consult their healthcare provider before use.

Avoid Interactions

TePadina 400 mg may interact with other medications, particularly those that affect the bone marrow or immune system. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain CYP inhibitors may also affect the metabolism and efficacy of Thiotepa.

Frequently Asked Questions

TePadina 400 mg is primarily used in medical settings for its cytotoxic properties, often in chemotherapy.

TePadina 400 mg is administered intravenously as a powder for solution.

Common effects may include nausea, vomiting, fatigue, and bone marrow suppression.

Pregnant women and individuals with certain medical conditions should consult their healthcare provider before using TePadina 400 mg.

Yes, TePadina 400 mg may interact with medications that affect the bone marrow or immune system.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.